Crinetics Pharmaceuticals, Inc.
CRNX
$35.70
-$0.35-0.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -52.39% | -69.33% | -56.15% | -44.59% | -34.11% |
| Total Depreciation and Amortization | 26.14% | 31.43% | 27.36% | 95.15% | 200.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.25% | 29.04% | 36.50% | 55.24% | 18.60% |
| Change in Net Operating Assets | 470.14% | 30.53% | -29.59% | -454.27% | -130.18% |
| Cash from Operations | -38.93% | -76.24% | -80.19% | -67.35% | -73.62% |
| Capital Expenditure | 55.49% | -63.45% | -235.29% | 6.98% | -10.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 110.64% | 684.02% | 178.11% | -5,262.83% | -526.42% |
| Cash from Investing | 110.53% | 699.93% | 170.75% | -27,919.09% | -520.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.31% | -94.76% | 50.81% | -98.92% | 1,328.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 203.42% |
| Cash from Financing | -95.32% | -94.62% | -6.22% | -98.87% | 1,366.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 81.29% | 278.47% | 56.44% | -149.84% | 40.02% |